MAZE Maze Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1842295 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-20.1%
TTM EPS YoY32.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-37.5%
ROA-32.4%
ROIC (approx.)-69.0%
Asset turnover—
Leverage & solvency
Liabilities / assets16.2%
Debt / equity0.09x
Current ratio14.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $20.00M | — | — | $0 | — | $0 |
| R&D expense | $40.22M | $34.94M | $34.15M | $27.57M | $25.19M | $28.11M | $27.58M | $22.22M |
| SG&A expense | $11.30M | $13.10M | $12.40M | $10.49M | $7.78M | $8.37M | $7.82M | $7.51M |
| Operating income | -$51.52M | -$48.03M | -$26.55M | -$38.06M | -$32.97M | -$36.47M | -$35.40M | -$29.73M |
| Interest expense | $975,000 | $931,000 | $866,000 | — | — | — | — | — |
| Pretax income | — | — | — | -$34.57M | -$30.09M | -$33.68M | -$32.79M | -$29.85M |
| Income tax | — | — | — | $0 | $0 | $0 | — | -$275,000 |
| Net income | -$47.97M | -$44.73M | -$24.21M | -$34.57M | -$30.09M | -$33.68M | -$32.79M | -$29.58M |
| EBITDA | -$51.13M | -$47.64M | -$26.11M | -$37.56M | -$32.39M | -$35.83M | -$34.72M | -$29.02M |
| EPS (basic) | -0.79 | -0.76 | -0.45 | — | -0.66 | -0.77 | -1.15 | — |
| EPS (diluted) | -0.79 | -0.76 | -0.45 | — | -0.66 | -0.77 | -1.15 | — |
| Weighted avg. shares (diluted) | 60.86M | 59.00M | 53.90M | — | 45.78M | 43.80M | 28.63M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $154.16M | $202.64M | $198.77M | $189.25M | $316.77M | $264.54M | $294.37M | $197.90M |
| Short-term investments | $235.50M | $208.44M | $153.62M | $152.67M | $67.16M | — | — | — |
| Receivables | — | — | $20.00M | — | — | — | — | — |
| Current assets | $400.10M | $420.42M | $379.78M | $349.72M | $391.30M | $271.15M | $299.71M | $201.67M |
| PP&E, net | $4.35M | $4.39M | $4.68M | $5.04M | $5.54M | $6.01M | $6.31M | $6.67M |
| Total assets | $511.56M | $531.62M | $419.71M | $397.13M | $422.06M | $303.52M | $332.84M | $240.54M |
| Current liabilities | $28.30M | $22.96M | $21.24M | $22.56M | $22.11M | $19.90M | $18.62M | $20.67M |
| Short-term debt | $0 | $0 | $0 | — | — | — | — | — |
| Long-term debt | $39.12M | $38.96M | $38.83M | — | — | — | — | — |
| Total debt | $39.12M | $38.96M | $38.83M | — | — | — | — | — |
| Total liabilities | $83.01M | $78.50M | $78.01M | $42.16M | $42.62M | $41.28M | $40.77M | $43.64M |
| Shareholders' equity | $428.55M | $453.12M | $341.70M | $354.97M | $379.44M | $262.24M | $292.07M | -$311.18M |
| Net debt | -$115.03M | -$163.68M | -$159.93M | — | — | — | — | — |
| Shares outstanding | 56.45M | 55.50M | 49.74M | 49.34M | 48.08M | 43.85M | 43.80M | 2.45M |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.84M | -$15.05M | -$39.11M | -$27.73M | -$24.64M | -$30.05M | -$29.52M | -$22.45M |
| Capital expenditure | $288,000 | $107,000 | $93,000 | $34,000 | $68,000 | $393,000 | $299,000 | $605,000 |
| Free cash flow | -$33.13M | -$15.16M | -$39.21M | -$27.76M | -$24.71M | -$30.45M | -$29.82M | -$23.06M |
| Investing cash flow | -$31.41M | -$128.51M | $6.28M | -$103.39M | -$66.88M | -$393,000 | -$299,000 | -$605,000 |
| Financing cash flow | $15.77M | $147.44M | $42.36M | $3.59M | $143.76M | $612,000 | $127.38M | $70.26M |
| Depreciation & amortization | $385,000 | $391,000 | $444,000 | $499,000 | $571,000 | $649,000 | $684,000 | $705,000 |
| Stock-based compensation | $8.54M | $9.19M | $7.11M | $6.07M | $3.86M | $3.24M | $3.23M | $2.85M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.